MEDALIST: Luspatercept in MDS - Capsule Summary Slidesets - MDS and MPNs - 2019 ASH Annual Meeting - Oncology - Clinical Care Options
Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes | Leukemia
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes | NEJM
Acceleron And Celgene Deliver Strong Results In The Phase 3 MEDALIST Trial (NASDAQ:CELG) | Seeking Alpha
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia | NEJM
Reblozyl® (luspatercept-aamt) MEDALIST Trial Details | MDS-RS
REBLOZYL® for Treatment of Anaemia Associated with Beta-Thalassemia
-Associated%20Myelofibrosis,%20beta-Thalassemia,%20Myeloproliferative%20Disorders,%20Thalassemia,%20Myelodysplastic%20Syndromes%20(MDS):%0A%0ALuspatercept%20for%20Thalassemia.png?md=1 "Luspatercept for Thalassemia Clinical Trial 2022 | Power")
Luspatercept for Thalassemia Clinical Trial 2022 | Power
Reblozyl® (luspatercept-aamt) Efficacy|BELIEVE Trial|Baseline|Results
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study - The Lancet Oncology
Phase 3 Trial of Luspatercept for Transfusion-Dependent β-Thalassemia | NEJM
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia | NEJM
Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis - ScienceDirect
Luspatercept for Myelodysplastic Syndromes Clinical Trial 2022 | Power
Reblozyl – TIF
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis | Leukemia
Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia. - Abstract - Europe PMC
Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis - ScienceDirect
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes | NEJM
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study - The Lancet Oncology
Luspatercept for the treatment of β-thalassemia: from preclinical research to clinical practice and beyond | Future Rare Diseases
Acceleron: Luspatercept New Data Is A Buy Signal (NYSE:MRK) | Seeking Alpha
Luspatercept: First Approval | SpringerLink
Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes - Chen - 2020 - CPT: Pharmacometrics & Systems Pharmacology - Wiley Online Library
